Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, Uttar Pradesh, India.
Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar 90245, Indonesia.
J Infect Public Health. 2023 Jan;16(1):4-14. doi: 10.1016/j.jiph.2022.11.024. Epub 2022 Nov 19.
Newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are continuously posing high global public health concerns and panic resulting in waves of coronavirus disease 2019 (COVID-19) pandemic. Depending on the extent of genomic variations, mutations and adaptation, few of the variants gain the ability to spread quickly across many countries, acquire higher virulency and ability to cause severe disease, morbidity and mortality. These variants have been implicated in lessening the efficacy of the current COVID-19 vaccines and immunotherapies resulting in break-through viral infections in vaccinated individuals and recovered patients. Altogether, these could hinder the protective herd immunity to be achieved through the ongoing progressive COVID-19 vaccination. Currently, the only variant of interest of SARS-CoV-2 is Omicron that was first identified in South Africa. In this review, we present the overview on the emerging SARS-CoV-2 variants with a special focus on the Omicron variant, its lineages and hybrid variants. We discuss the hypotheses of the origin, genetic change and underlying molecular mechanism behind higher transmissibility and immune escape of Omicron variant. Major concerns related to Omicron including the efficacy of the current available immunotherapeutics and vaccines, transmissibility, disease severity, and mortality are discussed. In the last part, challenges and strategies to counter Omicron variant, its lineages and hybrid variants amid the ongoing COVID-19 pandemic are presented.
新型严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)不断出现,对全球公共卫生造成高度关注和恐慌,导致 2019 年冠状病毒病(COVID-19)大流行一波又一波。根据基因组变异、突变和适应的程度,少数变异株具有在许多国家迅速传播的能力,获得更高的毒力和引起严重疾病、发病率和死亡率的能力。这些变异株已被证明会降低当前 COVID-19 疫苗和免疫疗法的效果,导致接种疫苗的个体和康复患者发生突破性病毒感染。总的来说,这可能会阻碍通过正在进行的 COVID-19 疫苗接种来实现的保护性群体免疫。目前,唯一值得关注的 SARS-CoV-2 变异株是首先在南非发现的奥密克戎。在这篇综述中,我们介绍了新兴的 SARS-CoV-2 变异株的概述,特别关注奥密克戎变异株、其谱系和杂交变异株。我们讨论了奥密克戎变异株更高的传染性和免疫逃逸的起源、遗传变化和潜在分子机制的假设。讨论了与奥密克戎相关的主要问题,包括当前可用的免疫疗法和疫苗的疗效、传染性、疾病严重程度和死亡率。最后一部分介绍了在当前 COVID-19 大流行期间应对奥密克戎变异株、其谱系和杂交变异株的挑战和策略。